Protecting a blockbuster diabetes treatment for AstraZeneca
AstraZeneca AB
Major victories across IP venues for Volkswagen, Audi, Bentley, and Lamborghini
Audi AG; Audi of America, LLC; Automobili Lamborghini America, LLC; Automobili Lamborghini S.p.A.; Bentley Motors Limited; Bentley Motors, Inc; Volkswagen AG; Volkswagen Group of America, Inc.
No confusion in trademark victory on summary judgment for the American Retirement Association
American Retirement Association
Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million
Intellia Therapeutics, Inc.
Finnegan secures favorable ITC ruling related to innovative electric SUVs for BMW
BMW of North America, LLC and Bayerische Motoren Werke AG
Finnegan fights for Sony’s “exceedingly famous” mark
Sony Group Corporation
Experience
Certain Plant-Derived Recombinant Human Serum Albumins ("rHSA") and Products Containing Same Certain Plant-Derived Recombinant Human Serum Albumins ("rHSA") and Products Containing Same
337-TA-1238, ITC, Judge McNamara
Experience
Prosecuting patents for startup Hutchison Medipharma Prosecuting patents for startup Hutchison Medipharma
Hutchison Medipharma
Experience
Two-Way Radio Equipment and Systems, Related Software, and Components Thereof Two-Way Radio Equipment and Systems, Related Software, and Components Thereof
337-TA-1053, ITC, Judge McNamara
Experience
Complete victory for Finnegan clients Nutrichem and Heyi at the ITC Complete victory for Finnegan clients Nutrichem and Heyi at the ITC
337-TA-914, ITC, Judge Lord
Experience
Certain Light Emitting Diode Chips, Laser Diode Chips and Products Containing Same Certain Light Emitting Diode Chips, Laser Diode Chips and Products Containing Same
337-TA-674, ITC, Judge Luckern
Experience
Certain Short-Wavelength Light Emitting Diodes, Laser Diodes and Products Containing Same Certain Short-Wavelength Light Emitting Diodes, Laser Diodes and Products Containing Same
337-TA-640, ITC, Judge Luckern
Experience
When the patent for Zyprexa® and $2 billion in annual revenue were on the line, Eli Lilly turned to Finnegan When the patent for Zyprexa® and $2 billion in annual revenue were on the line, Eli Lilly turned to Finnegan
1:01-cv-00443, S.D. Ind., Judges LaRue, Lynch, Shields, Young
05-1429, -1430, Fed. Cir., Judges Rader, Schall, Gajarsa
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.